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Abstract
Background: Recent studies have revealed the positive antiproliferative and cytotoxic effects of antiviral agents in
cancer treatment. The real effect of adjuvant antiviral therapy is still controversial due to the lack of studies in biochemical
mechanisms. Here, we studied the effect of the antiviral agent acyclovir on morphometric and migratory features of the
MCF7 breast cancer cell line. Molecular levels of various proteins have also been examined.
Methods: To evaluate and assess the effect of antiviral treatment on morphometric, migratory and other cellular
characteristics of MCF7 breast cancer cells, the following experiments were performed: (i) MTT assay to measure the
viability of MCF7 cells; (ii) Colony formation ability by soft agar assay; (iii) Morphometric characterization by
immunofluorescent analysis using confocal microscopy; (iv) wound healing and transwell membrane assays to
evaluate migration and invasion capacity of the cells; (v) ELISA colorimetric assays to assess expression levels of caspase-3,
E-cadherin and enzymatic activity of aldehyde dehydrogenase (ALDH).
Results: We demonstrate the suppressive effect of acyclovir on breast cancer cells. Acyclovir treatment decreases the
growth and the proliferation rate of cells and correlates with the upregulated levels of apoptosis associated cytokine
Caspase-3. Moreover, acyclovir inhibits colony formation ability and cell invasion capacity of the cancer cells while
enhancing the expression of E-cadherin protein in MCF7 cells. Breast cancer cells are characterized by high
ALDH activity and associated with upregulated proliferation and invasion. According to this study, acyclovir
downregulates ALDH activity in MCF7 cells.
Conclusions: These results are encouraging and demonstrate the possibility of partial suppression of cancer
cell proliferation using an antiviral agent. Acyclovir antiviral agents have a great potential as an adjuvant therapy in the
cancer treatment. However, more research is necessary to identify relevant biochemical mechanisms by which acyclovir
induces a potent anti-cancer effect.
Keywords: MCF7 breast cancer cell line, Acyclovir, Antiproliferative effect, ALDH activity
Background
Current cancer therapy includes the use of chemothera-
peutic agents, surgery and radiation therapy. It is esti-
mated that four types of viruses alone could cause 12%
of cancer cases worldwide. These are human papilloma-
virus (HPV), hepatitis B (HBV), hepatitis C (HCV), and
Epstein–Barr virus (EBV) [1]. Investigation of the virus-
associated cancer serves as a unique platform for the
development of novel strategies to prevent the develop-
ment of infection that can predispose tumorigenesis. Stud-
ies on antiviral drug treatments demonstrate promising
results on the prognosis through the prevention of car-
cinogenesis. Administration of the antiviral agents in com-
bination with the anticancer drugs is known for positively
influencing the effectiveness of the treatment [2]. This
combined therapy is termed as an adjuvant antiviral ther-
apy [3]. Complex combinations of the chemotherapeutic
agents together with the antiviral drugs are used to treat a
number of infection-associated malignancies such as
Kaposi sarcoma, hepatocellular carcinoma (HCC) and
nasopharyngeal carcinoma [4, 5]. A study based on the
electronic health records of 2671 adult participants diag-
nosed with chronic HBV infection from 1992 to 2011 also
indicates that an antiviral treatment against chronic HBV* Correspondence: dana.akilbekova@nu.edu.kz1National Laboratory Astana, Nazarbayev University, Qabanbay Batyr Avenue
53, Astana 010000, Kazakhstan
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Shaimerdenova et al. Infectious Agents and Cancer  (2017) 12:18 
DOI 10.1186/s13027-017-0128-7
infection markedly decreases the incidence of HCC in the
treated patients [5].
Adjuvant antiviral therapy also has a reported antipro-
liferative effect in some types of cancer [2]. Treatment of
breast cancer cells with ribavirin decreases the level of
one of the biomarkers of this malignancy, eukaryotic
translation initiation factor (eIF4E), which is usually ele-
vated in more than 25% of cancer cases [6]. Ribavirin
disrupts the structure of eIF4E, leading to the inhibition
of cyclin D1 and expression of NBS1 oncogene [7, 8].
Namba et al. demonstrated the use of zidovudine, an
antiviral drug, in combination with gemcitabine, a che-
motherapeutic agent - in an attempt to overcome a gem-
citabine resistance for the pancreatic cancer treatment.
In this type of malignancy, the gemcitabine resistance is
associated with a decreased level of human equilibrative
nucleoside transporter 1 (hENT1) and acquisition of epi-
thelial-to-mesenchymal transition (EMT) - like phenotype.
The zidovudine adjunct therapy was shown to reverse
both events in this study [9]. Furthermore, authors dem-
onstrated that activation of Akt-GSK3β-Snail mechanism,
one of the major signaling pathways during gemcitabine
resistance, is inhibited by zidovudine so that gemcitabine-
resistant cancer cells were resensitized.
Although there is a plethora of evidence suggesting
the beneficial effect of the antiviral agents in cancer
treatment, the therapeutic benefit of their use in cancer
treatment remains a grey area due to the lack of studies
of the biochemical mechanisms. Antiviral agents such as
acyclovir and ribavirin have been reported to have a sup-
pressive effect on the proliferation and ability to increase
an apoptosis in various cancers [7, 8]. Acyclovir was dis-
covered 40 years ago and remains one of the main exist-
ing therapies for herpes simplex virus (HSV) infections.
This drug is a highly potent inhibitor of this virus and
commonly used for the treatment of the infections
caused by the herpes viruses, CMV and EBV. It also has
a low toxicity for the normal cells [10].
In the present study, we propose to investigate how
cancer cells respond to the antiviral agent as acyclovir in
vitro and whether this treatment can affect the meta-
static phenotype of cancer cells. We report results on
the potential effect of acyclovir treatment on the cell
proliferation, invasion capacity, cytotoxicity, and the
expression of tumor suppressing genes.
Methods
Cell culture
Breast cancer cell line MCF7 (American Type Cell
Collection, ATCC® HTB 22™) and human breast epithe-
lial primary cells (Celprogen, Benelux, Netherlands) were
cultured in a complete media (CM) (Dulbecco’s modified
Eagle’s medium (DMEM) (D6421, Sigma-Aldrich, St
Louis, MO, USA) supplemented with 10% fetal bovine
serum (12103C-500 ml, Sigma-Aldrich, Buchs, Switzerland),
100 U/mL penicillin, 100 μg/mL streptomycin and 25 ug/
mL Amphotericin B (SV30079.01, HyClone, Thermo
Scientific, South Logan, Utah, USA) at 37 °C in 5% CO2.
Cells were subcultured every three days using 0.25% tryp-
sin-EDTA (25-052-CI, Cellgro, Mediatech Inc, Manas-
sas, VA, USA) for detachment.
Treatment with Acyclovir
Antiviral agent – acyclovir (ACV) in powder form was
purchased from Sigma-Aldrich (PHR1254-1G, St Louis,
MO, USA). A 10 mM (stock) solution was prepared in
phosphate buffered saline (PBS) and sterilized through
filtering (0.45 μM PVDF 25 mm filters, (094.01.003, Iso-
lab, Wertheim, Germany). Stock solution was stored at
-20 °C. MCF7 cells were cultured in 12-well plate at
26,000 cells/cm2 (92412, TPP, Switzerland) in the pres-
ence of 5 uM acyclovir solution and incubated for 72 h
at 37 °C in 5% CO2. In a positive control experiment,
cells were cultured in the absence of acyclovir. A control
of acyclovir without cells was also conducted. All experi-
ments were performed in triplicate.
Viability assay
Cell viability after the acyclovir treatment was evaluated
with MTT (3-(4,5-dimethylthiazol-2- yl)-2,5-diphenyltet-
razolium bromide (M5655-1G, Sigma Aldrich, St Louis,
MO, USA) assay. Concentration of 5 mg/ml was
achieved by reconstituting MTT in DI water. After re-
moval of the supernatant from the wells, 500 μl of warm
culture media and 50 μl of MTT solution were added in
each well for two hours at 37 °C in 5% CO2. Then
400 μl of media was removed and crystals of formazan
were diluted with 500 μl of dimethyl sulfoxide (DMSO)
(D4540-100 ml, Sigma Aldrich, St Louis, MO, USA).
Absorbance of cells was measured at 570 nm (BioTek
ELx800 plate reader, Winooski, Vermont, USA).
Proliferation assay
Proliferation in MCF7 cells was determined by plating
6500 cells/cm2 into 12-well plate and cultured in a
medium with and without ACV. After overnight incuba-
tion cells were detached with trypsin and counted using
automated cell counter (TC20™, 1450102, Bio-rad
Laboratories, Berkeley, California) at 24, 48, 72 and 96 h.
Soft agar assay
The ability of cancer cells to form colonies was charac-
terized using a soft agar assay. This assay required
21 days of growth on the soft agar medium. At the end
of 3 weeks, a number of colonies formed per petri dish
were counted using a crystal violet stain. Briefly, 1% ster-
ile agar solution was warmed in a microwave and place
to 37 °C water bath to cool down. 500 μg of agarose
Shaimerdenova et al. Infectious Agents and Cancer  (2017) 12:18 Page 2 of 10
powder (BP165-25, Thermo Fisher Scientific, Fair Lawn,
New Jersey, USA) was dissolved in 50 mL distilled water.
The bottom of the petri dish (502014-07P, Sterilin petri
dishes 9.6 cm2, Dynalon Labware, Rochester, NY, USA)
was coated with 0.7% agar and 0.3% CM by adding
3 ml/dish at room temperature for 30 min. following
this, the upper layer of 3 mL of agar solution with 0.3%
agar and 0.7% cell suspension (3125 cells/cm2) was
plated. The top agar layer was allowed to solidify and
then incubated for 3 weeks at 37 °C in 5% CO2. CM was
refreshed 2 times a week. In 21 days crystal violet was
used as a staining for colonies (C3886, Sigma-Aldrich,
Munich, Germany) and counting was performed using
Leica DMI3000 B light microscope.
Cell staining for fluorescent imaging
Morphological analysis
Glass coverslips were cleaned for 2 h in 200 mL ethanol,
50 g NaOH, and 300 mL DI water and finally rinsed
with PBS. Cells were seeded on glass coverslips at 10,500
cells/cm2, placed in petri dishes (Sterilin petri dishes
9.6 cm2) and incubated at 37 °C in 5% CO2 overnight
before the treatment. After the 72 h incubation with
acyclovir, coverslips with cells were rinsed briefly with
PBS for thrice for 5 min each time. 4% paraformalde-
hyde was used as a fixative for 10 min at room
temperature. The samples were blocked with 1% BSA
and 0.3% Tween-20 (P2287-500 ml, Sigma-Aldrich, St
Louis, MO, USA) in PBS and incubated at room
temperature for 1 h. Following 1 h incubation, α-tubulin
rabbit mAb Alexa Fluor® 488 conjugate (322588, Invitro-
gen, Life Technologies, Rockford, IL, USA) diluted as
1:200 was used for staining and incubation at 4 °C over-
night in the dark. After 24 h, the coverslips were washed
3 times for 5 min with PBS and then incubated with
0.1 μg/mL DAPI for 2 min. After rinsing again with
PBS, aqueous mounting medium (ab128982, Abcam,
Cambridge, MA) was used for mounting coverslips on
microscope slides. Finally, coverslips were sealed with
a clear nail polish. Images were acquired using EVOS®
FLoid® Cell Imaging Station (4471136, Life Technolo-
gies, Carlsbad, California, USA). Cellprofiler software
was used to evaluate morphometric features of treated
MCF7 cells (Broad Institute, www.cellprofiler.org).
The equation used for the quantitative measurement
of the shape of the cell is given below. This equation
uses form factor, FF:
FF ¼ 4  π  area=perimeter2 ð1Þ
The pipeline for this analysis included four modules:
Identify Primary Objects, Identify Secondary Objects, Iden-
tify Tertiary Objects and Measure Object Size Shape [11].
Area ratio was calculated by dividing area of nucleus over
area of cytoplasm.
Immunofluorescence staining for the presence of E-cadherin
4% paraformaldehyde in PBS was used as a fixative for
10 min at room temperature and 0.1% Triton was used
as a permeabilization solution for 10 min on ice. Follow-
ing this, cells were washed 3 times with ice cold PBS
and blocked with 1% BSA in PBST at room temperature
for 1 h. Blocked cells were stained with 1 mg/ml of Ms
mAb to E-cadherin (ab1416, Abcam, Cambridge, MA,
USA) in 1% BSA in PBST in a humidified chamber for
24 h at 4 °C. The stained samples were then washed 3x5
min with PBS and incubated overnight with a 2 mg/ml
of secondary antibody goat pAb to Ms IgG Alexa fluor
488 (ab150113, Abcam, Cambridge, MA, USA) in 1%
BSA in PBST. Coverslips were washed 3x5 min with
PBS in the dark and incubated with DAPI for 2 min, and
mounted on the microscope slides using glycerol. Images
were acquired using EVOS® FLoid® Cell Imaging Station
(4471136, Life Technologies, Carlsbad, California, USA).
Aldehyde dehydrogenase activity colorimetric assay (ALDH)
NAD-dependent ALDH activity was measured using col-
orimetric assay kit (MAK082-1KT, Sigma Aldrich, Saint
Louis, MO, USA) and performed as described in the
manufacturer’s instructions. The absorbance was mea-
sured at 450 nm on BioTek ELx800 plate reader. Mea-
surements were recorded every 3 min until the value of
the control sample exceeded the value of the most active
standard (10 nmole/well). The following equation was
used to calculate the activity of the enzyme:
ALDH Activity ¼ NADH Amount nmoleð Þ x Sample Dilution Factor
Reaction timeð Þ x Sample volume mLð Þ
ð2Þ
Transwell migration assay
Cells were cultured for 72 h with and without acyclovir
at 37 °C in 5% CO2, and then in serum-free medium for
another 24 h at 37 °C in 5% CO2. After detachment with
0.05% trypsin- EDTA the cells were re-suspended in a
serum-free medium. Upper insert was filled with 100 μl
of the cell suspension (~9x104-1x106 cells per well)
while reservoir chamber was filled with 600 μl of culture
medium. Migration of cells was monitored at 3, 6, and
12 h at 37 °C in 5% CO2. Crystal violet was used as the
staining solution to distinguish between migrated and
non-migrated cells. A cotton swab was used to remove
the cells that were left in the upper chamber of the
membrane. Those cells that migrated through the insert
were examined and counted with bright-field microscope
(LEICA DMI3000 B, Wetzlar, Germany).
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Wound healing
Cell culture was performed at a concentration of
260,000 cells/cm2 in 12-well plates incubated overnight
at 37 °C in 5% CO2. The medium was then substituted
with CO2 free media with and without ACV. A scratch
using sharpened toothpick was made on the surface of
the well to simulate a wound in vitro. Four randomly
areas in a well were selected and imaged in 10 min inter-
vals for 12 h using time-lapse microscopy system
(AMAFD1000, EVOS FL Auto imaging system, Life
Technologies, Thermo Fisher Scientific, Carlsbad, CA,
USA). The images obtained were processed using ImageJ
(image processing software). The sequence of images
was analyzed and the open wound area was measured
for each image at every hour. A scatter plot of wound
area measurements (units) vs. time (in hours) was gener-
ated as seen in Additional data 5. A line-of-best fit was
used to calculate the slope, which corresponded to the
rate of migrated cells.
E-cadherin, C-Myc, NF-kB p65 and caspase-3 levels
colorimetric assays
Secretion levels of E-cadherin in a cell culture were mea-
sured using a human E-cadherin ELISA colorimetric
assay kit (99-1700, Invitrogen, Novex by Life Technolo-
gies, Frederick, MD, USA) and performed as described
in the manufacturer’s instructions. Cellular levels of C-
Myc, NF-kB p65 and caspase-3 in cell lysates were mea-
sured using a human C-Myc ELISA colorimetric assay
kit (KHO 2041, Novex by Life Technologies, Frederick,
MD, USA); a human NF-kB p65 Total ELISA colorimet-
ric assay kit (KHO 0371, Novex by Life Technologies,
Frederick, MD, USA) and a human caspase-3 ELISA
Kit (KHO 1091, Novex by Life Technologies, Frederick,
MD, USA).
Cell lysates were prepared using a 1 mM phenyl-
methylsulfonyl fluoride (PMSF) cell extraction buffer, a
protease inhibitor cocktail (78439, Thermo Scientific,
Rockford, IL, USA) and RIPA buffer (89900, Thermo
Scientific, Rockford, IL, USA). Lysis was performed by
adding 500 μl extraction buffer to the cell pellet for
30 min on ice while vortexing every 10 min. Then the
cells were placed in the microcentrifuge tubes at
13,000 rpm for 10 min at 4 °C. Lysates were stored at
-80 °C. All experiments were performed in triplicate.
Results were expressed as mean concentration ± stand-
ard deviation and normalized to the number of live cells.
Apoptosis assay
Programmed cell death was studied using annexin
V-FITC apoptosis detection kit (331200, Invitrogen,
Camarillo, CA, USA). Treated and control cells were
harvested and re-suspended in CM to obtain a target
concentration of 1×106/ml in 1.5 ml Eppendorf tubes.
Cells were centrifuged for 1 min at 3000 rpm, washed
with ice cold PBS and centrifuged again. Cell pellets
were re-suspended in 190 ul of 1x binding buffer with
10 ul Annexin V-FITC and 10 ul of 20ug/ml propidium
iodide for 15 min at room temperature in the dark.
Apoptosis of the cells was analyzed by flow cytometry
(SORP FACSAria -II with 6 lasers, BD Biosciences, San
Jose, USA).
Statistics
All reported results below are presented as mean values
± standard error values. To calculate differences between
means, one-way analysis of variance (ANOVA) was im-
plemented, where a null hypothesis was accepted when
all means were equal. Population differences were calcu-
lated only for a treatment and a control within the cell
line. If at least one mean was different, a follow-up
Tukey’s HSD test to compare between groups and calcu-
late p-values of each sample (α = 0.05).
Results
Viability of MCF7 cells and breast epithelial cells after
the treatment with 5 μM ACV were measured and nor-
malized to the untreated culture cells [Additional file 1].
MCF7 cells and breast epithelial cells demonstrated
80,687 and 97,194% of viable cells after the ACV treat-
ment, respectively.
First, we sought to evaluate the influence of ACV on the
proliferation ability and apoptosis of MCF7 cells. Regu-
lated interplay between apoptosis and cell proliferation is
essential for the processes like tissue development and de-
regulation mechanisms [12]. Deregulated mechanism of
apoptosis that correlates with an uncontrolled cell prolif-
eration eventually leads to the carcinogenesis [13]. Several
antiviral agents demonstrated the ability to inhibit prolif-
eration and increase proapoptotic activity of the cancer
cells [2]. Here, the rate of proliferation decreased during
96 h treatment with ACV (Fig. 1a). ACV significantly in-
creased a population doubling time compared to the
control cells ∾1.4 fold [Additional file 2]. Caspase-3 level
in MCF7 cells was estimated to evaluate the apoptotic ac-
tivity of cancer cells in response to ACV treatment. ACV
upregulated caspase-3 expression in the treated cells ∾1.7
compared to the control cells (p < 0.05) (Fig. 1b). Annexin
V staining and flow cytometry analysis demonstrated a
slight increase of the number of the apoptotic cells in re-
sponse to ACV treatment (p > 0.05 for the late and early
apoptosis) (Fig. 1c, Additional file 3).
When examining normal cells and cancerous cells
under the microscope, we observed distinctive external
characteristic features. Results of the IF staining indicate
that cancer cells underwent changes in their morpho-
logical characteristics in response to ACV treatment
(Fig. 1d). FF shape descriptor was used quantitative
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characterization of these changes, where FF value of 1
served as a detector of a circular shape and 0 indicated
linear or star shaped object [Additional file 4]. ACV
treated cancer cells displayed a decrease of FF compared
to the control cells from 0.828 ± 0.014 to 0.659 ± 0.012,
indicating that ACV treated cells were more spread out
with a non-uniform shape (∾1.25 fold). Furthermore,
ACV treated cancer cells had a larger cytoplasmic vol-
ume compared to the control cells.
The effect of ACV treatment on the migratory and in-
vasive capacities of the breast cancer cells was also
tested. Various environmental factors can modulate the
motility of cancer cells and affect invasion capacity of
these cells. Teng et al. showed that antiviral drug ribavi-
rin causes a considerable suppression of the migration of
renal cell carcinoma cell lines [14]. Boyden chamber mi-
gration assay was performed to assess whether ACV
affects MCF7 chemopolarised migration. As seen in
Fig. 2a, ACV treatment reduces the number of cells mi-
grating towards the chemoattractants as compared to
the control cells. The cell invasion capacity of the
treated cancer cells dropped ∾15 times compared to the
untreated cells (p < 0.05). Fig. 2b shows the effect of
ACV on the collective motility and rates of migration of
both normal and cancer cells. The rate of the wound
closure of ACV treated cancer cells decreased signifi-
cantly compared to the control cells with ∾1.34 fold and
was comparable to the rate of normal breast epithelial
cells (24.74 μm/h and 21.95 μm/h for ACV treated and
normal cells, respectively) (p < 0.05) [Additional file 5].
E-cadherin is secreted in most of the epithelial tissues
and normal expression of E-cadherin has been reported to
inhibit metastasis and invasion by suppressing epithelial-
mesenchymal transition as well as stimulating cell-cell
Fig. 1 The effect of ACV treatment on proliferation and morphometric features of MCF7 cells. a Relative cell number of MCF7 cells proliferation.
Cells were counted at 0, 24, 48 and 72 h post treatment. b Caspase-3 activity (ng/10^6 cells) in MCF7 cells treated with ACV. c Annexin V staining
of apoptotic MCF7 cells. Left panel is bright field images; right panel is Annexin V staining images. Green is cells stained with FITC Annexin V. Magnification
10X on Microscope Cell Observer SD Carl Zeiss with CMOS ORCA-Flash 4.0 V2. d Nuclei and cytoskeleton staining of MCF7 cells. Blue is nuclei stained by
DAPI; green is cytoskeleton stained with anti- alpha tubulin antibody. Magnification 20X on Microscope Cell Observer SD Carl Zeiss with CMOS ORCA-Flash
4.0 V2. For better visualization color enhancement was applied using ZEN software (for current images only)
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adhesions [15, 16]. We observed a significant increase of
E-cadherin secretion in ACV treated cells compared to
the control ∾1,25 (p < 0.05) as shown in Fig. 2c, d.
Next, we evaluated the action of ACV on the ability of
MCF7 cells to form colonies. This distinguishing feature
of the cell transformation and its deregulated growth
served as a marker to distinguish between cancer and
normal cells, since normal cells do not have the ability
to grow in semisolid matrices [17]. ACV treatment ef-
fectively decreased (∾ 2 fold) the number of colonies
formed by cancer cells compared to the untreated cells
as seen in Fig. 3a. Also the differences in external fea-
tures are clearly observable in rough scabrous surface of
control cells (R - shape) versus smoother surface of
ACV treated cells (S -shape). (Fig. 3b).
The concentration changes of C-Myc protein secreted
by MCF7 cells were determined in response to ACV
treatment. C-Myc oncogene regulates cellular growth
and metabolic mechanisms as well as their interconnec-
tion [18]. Our results demonstrate a non-significant ef-
fect of ACV on the level of secretion of C-Myc in MCF7
cells. The concentration of C-Myc protein was similar to
the control (Fig. 4a). Additional examinations of the viral
protein NF-kB p65 demonstrated an elevated level after
treatment with ACV [Additional file 6].
ALDH activity is one of the detectors of cancer pro-
gression [19]. Upregulated expression of ALDH1, one of
the isoforms of ALDH family, has been reported as a
crucial event in the breast cancer prognosis correlated
with a poor clinical outcome [20, 21]. Moreover, studies
show that ALDH activity is linked to the differentiation
and expansion. It is also associated with a self-protective
ability [22]. Our assessment of the effect of ACV treat-
ment on ALDH activity of breast cancer cells shows a
Fig. 2 Migratory characteristics and E-cadherin expression of MCF7 cells in response to ACV treatment. a Migration of breast epithelial and MCF7
breast cancer cells through Transwell membrane. Migration percentage was counted at 3, 6 and 24 h post-seeding. b Rate of reaction of wound
healing of breast epithelial cells and MCF7 breast cancer cells. c E-cadherin expression (ng/10^6 cells) in MCF7 cells treated with ACV. d Immunofluorescence
staining of protein level of E-cadherin (green) in MCF7 cells after 3 and 7 days treatment. Nuclei are shown in blue. Error bars represent a 95% confidence
interval based on the standard deviation. (*) indicates p <0.05 as compared with other samples and for pairwise comparison. One way ANOVA tests followed
by Tukey’s test were used for statistical analysis. The data for each cell type were obtained from the same culture experiment
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significant decrease (~3 fold) of ALDH activity in MCF7
cells compared to the control cells (Fig. 4b).
Discussion
Recently, several antiviral agents have been found to pos-
sess the ability to decrease the rate of the cells’ prolifera-
tion and to promote apoptosis in cancer cells. However,
despite the compelling results supporting the clinical use
of antiviral agents as an adjuvant therapy in cancer treat-
ment, there is still a lack of studies of the biochemical
mechanisms of their anticancer effects [23, 24]. There are
several factors that might be involved in a therapeutic ap-
proach of the antiviral adjuvant therapy in cancer treat-
ment: an antiviral agent selectively targets cancer related
viruses or post-chemotherapy infections and may also re-
sult in the cytotoxic and antiproliferative effects on the
cancer cells, causing apoptosis [2]. Our implementation of
ACV as an antiviral strategy demonstrated a positive effect
on the prevention as well as successful predictive capabil-
ity in the treatment of various types of malignancies.
In this study, we used acyclovir (ACV) to examine the
potential of the antiviral treatment on MCF7 breast can-
cer cell line. Acyclovir is an antiviral drug used in treat-
ing infections of Herpesviridae family [25]. In several
studies antiviral agents similar to ACV were used as an
adjuvant therapy along with the chemotherapy [26, 27].
Records of the patients diagnosed with nasopharyngeal
carcinoma demonstrate a suppression of the tumor
growth for several months where injection of antiviral
was used in tandem with the chemotherapy [26]. More-
over, in situ hybridization shows that the tumor cell pop-
ulations were reduced in EBV-encoded RNAs [26]. In
another study, the effect of acyclic nucleoside phospho-
nate against HPV-associated cancer was examined. The
results indicate that the adjunct therapy using a cyto-
toxic drug and acyclic nucleoside phosphonates is more
effective than one therapy alone. The authors also report
an inhibited rate of the virus replication that led to a de-
creased expression of the viral oncoproteins and upregu-
lation of the tumor-suppressor genes [27].
Fig. 3 ACV altered ability to form colonies of MCF7 breast cancer cells (a) Number of colonies of MCF7 cells in response to ACV treatment.
b Representative images of colonies formed. Duration of growing on a soft agar was 21 days. Error bars represent a 95% confidence
interval based on the standard deviation. (*) indicates p <0.05 compared with control and other samples. One way ANOVA followed by Tukey’s test
were used for statistical analysis. The data for each cell type were taken from the same culture experiment
Fig. 4 a C-Myc (pg/10^3 cells) and (b) ALDH activity (nmol NADH/min/mg protein) expressions of MCF7 cells in response to ACV treatment. Error
bars represent 95% confidence interval based on the standard deviation. (*) indicate p <0.05 as compared with other samples and for pairwise
comparison. One way ANOVA tests followed by Tukey’s test were used for statistical analysis. The data for each cell type were obtained from the
same culture experiment
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Based on our results, we conclude that ACV as an
antiviral agent has a potential suppressive effect on
MCF7 breast cancer cells. ACV does not affect viability
of non-cancerous breast epithelial cells, while showing a
decrease of the viability of MCF7 breast cancer cells.
Observed morphological changes and apoptosis analysis
demonstrated the ability of ACV to affect the process of
programmed cell death of MCF7 cells. The mechanism
of apoptosis requires a number of proteins that regulate
a proper cell death. One of these proteins is caspase-3
which is included in a family of cysteine proteases [28].
An upregulated level of the apoptosis associated cyto-
kine Caspase-3 was detected in ACV treated cells, cor-
relating with the higher number of apoptotic cells and
decreased rate of the cancer cell proliferation. Previ-
ously, it was reported that zidovudine treatment com-
bined with a chemotherapeutic agent cisplatin has
increased the apoptosis level of head and neck cancer
cells [29]. This synergistic strategy of zidovudine and cis-
platin was shown to trigger abnormal regulation of the
mitochondria, increase of oxidative stress response and
cause a significant cytotoxic effect on the cancer cells
through the inhibition of a thiol metabolism [29]. Quan-
titative analysis revealed a moderate effect of acyclovir
with a slight increase of the apoptotic cells.
ACV was also able to decrease the rate of the growth,
colony formation ability, and cell invasion capacity of
MCF7 breast cancer cells. These observations correlate
with an upregulated secretion of E-cadherin in ACV
treated cells. As previously mentioned, E-cadherin is an
essential marker in the building of cell-to-cell adhesion
and downregulation of this protein leads to the stimula-
tion of invasion and metastasis [30].
Previous studies also report that antiviral agents can
affect the secretion of the specific translation initiation
factors, oncogenes, and angiogenic genes [8, 31, 32].
Borden et al. showed the ability of ribavirin to decrease
the oncogenic potential of eukaryotic translation initi-
ation factor (eIF4E) in the case of acute myeloid
leukemia with a poor prognosis. Ribavirin binds eIF4E
around the m7G cap-binding site leading to the reduc-
tion of affinity of this translation initiator factor [32].
While, we observed that ACV did not affect the expres-
sion levels of C-Myc oncogene, suggesting that antiviral
agents might have a selective impact on the secretion of
specific proteins.
Moreover, our study showed that acyclovir was able to
influence ALDH activity in the breast cancer cells. The
ALDH superfamily consists of 19 isoenzymes with vari-
ous cellular localizations, tissue/organ distributions and
functions. ALDH enzymes catalyze highly reactive alde-
hydes and some isoenzymes play structural roles related
to the osmoregulation and possess antioxidant functions
[30]. Following cancer stem cell theories, where cancer
is suggested to have a stem origin, ALDH was found to
be a common marker for both normal and cancer stem
cells [22, 33, 34]. Increased level of ALDH enzyme is an
indicator of a high tumorigenic potential of the cancer
cell and ability to self-renew and initiate tumor progres-
sion [21]. In the breast cancer cells upregulated expres-
sion of ALDH is associated with a poor clinical outcome
[19, 20]. Our results suggest that ACV affects multiple
aspects of cellular life related to the carcinogenesis and
ALDH fulfills the role of a marker for these changes.
A study by Curiel et al. reported that ACV had an in-
hibitory effect on one of the immune system components
as T-regulatory cells (Treg) in glioblastomas through the
suppression of indoleamine 2, 3-dioxygenase activity [35].
Another antiviral agent - ribavirin was also reported as an
immune response inducer in the renal cell carcinoma lines
through the downregulation of IL-10 expression and the
upregulation of TGF-β expression [14]. The mechanisms
by which ACV enables its anticancer effects might involve
an enhanced immune response of the cancer cells and fur-
ther study is required in this area.
There are several limitations in this study. All experi-
ments were performed in vitro only on one cell line.
Future research should focus on an adjuvant strategy of
different antiviral agents to determine whether a combina-
torial effect exists, and if so, which pathways are affected
during the mechanism. Additionally, an examination of
epigenetic modifications might serve as a platform for un-
derstanding the molecular mechanism underlying the
antiviral therapy.
Conclusion
In summary, we present evidence that ACV has an anti-
cancer effect on breast cancer cell line. Our study shows
that ACV was able to inhibit cancer cells proliferation,
colony formation ability and cell invasion capacity, while
having no effect on the secretion of certain tumor sup-
pressor genes. Treatment with ACV induced downregu-
lation of ALDH activity, suggesting a decrease of the
tumorigenic potential of the treated cancer cells. These
results provide new insights on the effect of antiviral
agents on the tumorigenesis and metastasis. However,
more research is necessary to identify the primary target
of ACV and maximize its potential.
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Additional file 1: Viability of MCF7 breast cancer and normal breast
epithelial cells in response to acyclovir. Error bars represent 95% confidence
interval based on the standard deviation. (*) indicates p <0.05 as compared
with other samples and for pairwise comparison. One way ANOVA followed
by Tukey’s test were used for statistical analysis. The data for each cell type
were taken from same culture experiment. (DOCX 144 kb)
Additional file 2: Population doubling time (hours) of proliferation of
MCF7 cells treated with ACV. Error bars represent 95% confidence interval
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based on the standard deviation. (*) indicates p <0.05 as compared with
other samples and for pairwise comparison. One way ANOVA followed
by Tukey’s test were used for statistical analysis. The data for each cell
type were taken from same culture experiment. (DOCX 301 kb)
Additional file 3: Annexin V staining of apoptotic MCF7 cells after
treatment with acyclovir. Left panel is early apoptosis, right panel is late
apoptosis. Error bars represent 95% confidence interval based on the
standard deviation. One way ANOVA followed by Tukey’s test were used
for statistical analysis. Means are not significant, p > 0.05. P-value for early
apoptosis = 1.31579; for late apoptosis = 0.91371. The data for each cell
type were taken from same culture experiment. (DOCX 288 kb)
Additional file 4: Quantitative analysis of nucleus and cytoplasm of MCF7
breast cancer cells without and with acyclovir treatment. (DOCX 10 kb)
Additional file 5: A scatter plot of measurements where best fit line
and a slope indicate rate of migrating cells. (DOCX 62 kb)
Additional file 6: NF-kB p65 (pg/10^3 cells) expression of MCF7 cells in
response to ACV treatment. Error bars represent 95% confidence interval
based on the standard deviation. (*) indicates p <0.05 as compared with
other samples and for pairwise comparison. One way ANOVA followed
by Tukey’s test were used for statistical analysis. The data for each cell
type were taken from the same culture experiment. (DOCX 28 kb)
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